Dolby Family Ventures led a $30m Series A round in MindImmune Therapeutics.

Dolby Family Ventures, an early stage venture firm, led a $30m Series A round in MindImmune Therapeutics, a venture-backed biotechnology company developing products that target the immunological drivers of neurodegenerative disease, with a participation from Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures and the Foundation for a Better World. "We’ve been deeply impressed by the progress MindImmune has made since our initial investment, and we believe that Isaac is well positioned to lead MindImmune as the company grows. The company’s novel approach to modulating neuroinflammation has the potential to change the treatment paradigm for Alzheimer’s and other neurodegenerative diseases," Reetika Bhardwaj, Dolby Family Ventures Principal.